Education
About Us
Working with TipRanks
Follow Us
Pharmadrug (TSE:PHRX)
:PHRX
PHRX Stock Chart & Stats
C$0.02
<C$0.01(33.33%)
At close: 4:00 PM EST
C$0.02
<C$0.01(33.33%)
Day’s Range― - ―
52-Week Range<C$0.01 - C$0.03
Previous CloseN/A
Volume5.00K
Average Volume (3M)101.80K
Market Cap
C$1.08M
Enterprise ValueC$2.57M
Total Cash (Recent Filing)C$17.72K
Total Debt (Recent Filing)C$1.43M
Price to Earnings (P/E)―
Beta-0.29
Next Earnings
May 06, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding108,234,380
10 Day Avg. Volume83,723
30 Day Avg. Volume101,798
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)-0.74
Price to Sales (P/S)0.00
P/FCF Ratio-1.35
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Regulatory And Partnership FocusA strategic emphasis on regulatory pathways and evaluating assets/partnerships is a durable business-model lever. Successful regulatory progress or distribution partnerships can enable commercialization, de-risk R&D spend, and convert pipeline value into recurring revenue over the medium term.
Lower Absolute Debt Vs Prior PeakDebt having declined from its 2019 peak improves financial flexibility relative to that high-water mark. Lower absolute leverage reduces interest and covenant pressure, extending operational runway and giving management more options to pursue partnerships or reorganize without acute debt overhang.
Improved Cash Burn Trend Vs Earlier YearsA demonstrable improvement in cash burn versus the 2021–2022 period indicates better cost control or smaller cash needs. If sustained, this structural improvement lengthens runway, reduces reliance on frequent financing, and allows more deliberate strategic decisions over the next several quarters.
Bears Say
Revenue Collapse To Near ZeroSustained near-zero revenue across multiple years is a profound structural weakness: without recurring sales, the company cannot generate internal funding for R&D or commercialization. This undermines long-term viability and forces dependence on external financing or asset disposals.
Negative Shareholder Equity (solvency Risk)Negative equity signals solvency strain and reduces creditor and investor confidence. It constrains access to conventional financing, may trigger covenants or creditor actions, and limits the company's ability to invest or pursue partnerships, posing a persistent structural constraint.
Consistent Negative Operating And Free Cash FlowPersistent negative operating and free cash flow means the business cannot self-fund operations or growth. Long-term reliance on external funding dilutes shareholders or increases leverage, reducing resilience to shocks and making sustained product development or commercialization harder.
Pharmadrug News
PHRX FAQ
What was Pharmadrug’s price range in the past 12 months?
Pharmadrug lowest stock price was <C$0.01 and its highest was C$0.03 in the past 12 months.
What is Pharmadrug’s market cap?
Pharmadrug’s market cap is C$1.08M.
When is Pharmadrug’s upcoming earnings report date?
Pharmadrug’s upcoming earnings report date is May 06, 2026 which is in 78 days.
How were Pharmadrug’s earnings last quarter?
Pharmadrug released its earnings results on Nov 24, 2025. The company reported -C$0.001 earnings per share for the quarter, missing the consensus estimate of N/A by -C$0.001.
Is Pharmadrug overvalued?
According to Wall Street analysts Pharmadrug’s price is currently Overvalued.
Does Pharmadrug pay dividends?
Pharmadrug does not currently pay dividends.
What is Pharmadrug’s EPS estimate?
Pharmadrug’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Pharmadrug have?
Pharmadrug has 108,234,380 shares outstanding.
What happened to Pharmadrug’s price movement after its last earnings report?
Pharmadrug reported an EPS of -C$0.001 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Pharmadrug?
Currently, no hedge funds are holding shares in TSE:PHRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Pharmadrug
Pharmadrug Inc. operates as a specialty pharmaceutical company. It focuses on the research, development, and commercialization of controlled-substances and natural medicines, such as psychedelics, cannabis, and naturally-derived approved drugs. It also imports and distributes medical cannabis to pharmacies in Germany and rest of the European Union; and owns and operates Super Smart, an entity building to elevate the use of functional mushrooms and psilocybin mushrooms. In addition, the company engages in the researching and reformulating established natural medicines. It has a research agreement with the University of Michigan to evaluate N, N-dimethyltryptamine's (DMT) potential role in normal, diseased, and altered states of consciousness, as well as an agreement with Southwest Research Institute for initiating non-clinical and clinical manufacturing of cepharanthine; and clinical trial agreement with Johns Hopkins University to conduct a clinical study comparing acute and enduring psychological and neural effects of DMT and an undisclosed potently active comparator molecule. The company was formerly known as Aura Health Inc. and changed its name to Pharmadrug Inc. in October 2019. The company is based in Toronto, Canada.
Technical Analysis
Mountain Valley MD
―
Revive Therapeutics
―
InnoCan Pharma
―
Ramm Pharma
―
Aion Therapeutic Inc
―
Options Prices
Currently, No data available
---